| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||
|
Pension
Elite |
11-Jan-2008 11:24
|
||||
|
x 0
x 0 Alert Admin |
coming down soon. |
||||
| Useful To Me Not Useful To Me | |||||
|
AK_Francis
Supreme |
11-Jan-2008 10:41
Yells: "Happy go lucky, cheers." |
||||
|
x 0
x 0 Alert Admin |
Pension, wonderling so fast to got it @ 1.02, at what time? And you recovered at what time the same at what price? Can share? Cheers. | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Pension
Elite |
11-Jan-2008 10:31
|
||||
|
x 0
x 1 Alert Admin |
i juz wonder how many ppl got  at 1.02, 1.01 and 1.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Pension
Elite |
11-Jan-2008 10:20
|
||||
|
x 0
x 0 Alert Admin |
yesterday high 1.02, shorted and covered. today 1 shorted and yet to cover. |
||||
| Useful To Me Not Useful To Me | |||||
|
jennlsk
Member |
11-Jan-2008 10:19
|
||||
|
x 0
x 0 Alert Admin |
Cool  !! Keep us posted wor! Nice to see value investors around
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
bengster68
Master |
11-Jan-2008 10:13
|
||||
|
x 0
x 0 Alert Admin |
Im a 0.3% shareholder of BIG. Pre-IPO investor of BIG. Have been following BIG for a long time and only bought into it more aggressively after Conor failed on 07/05/07. BIG is the last worthwhile takeover target in the DES industry. Never expected the share price to go so low during sub-prime sell-down. Confident this company will be a multi-bagger eventually. Next month I have another pre-IPO investment going for reverse takeover. After RTO im a 0.5% shareholder. Its a China company in Marine and Port business and has potential for multi-bagger investment. Maybe i will start a thread on this company couple of months later. |
||||
| Useful To Me Not Useful To Me | |||||
|
Pension
Elite |
11-Jan-2008 10:07
|
||||
|
x 0
x 0 Alert Admin |
yesterday very high vol, today very low, sign of danger coming. | ||||
| Useful To Me Not Useful To Me | |||||
|
jennlsk
Member |
11-Jan-2008 09:56
|
||||
|
x 0
x 0 Alert Admin |
Bengster, u seems to have much knowledge abt BIG & its product. Wonder if u r fr medical line. Just curious how many lots hv u vested since u hv done such intensive research. Must be a 'major' shsholder wor 
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Beetlewill
Member |
11-Jan-2008 09:51
|
||||
|
x 0
x 0 Alert Admin |
I think pple are waiting for you to short then start buying up.......
|
||||
| Useful To Me Not Useful To Me | |||||
|
Pension
Elite |
11-Jan-2008 09:48
|
||||
|
x 0
x 0 Alert Admin |
so many rosy picture painted, how come this counter no movement??? | ||||
| Useful To Me Not Useful To Me | |||||
|
Pension
Elite |
11-Jan-2008 08:58
|
||||
|
x 0
x 0 Alert Admin |
i will look out for opportunity to short. | ||||
| Useful To Me Not Useful To Me | |||||
|
novena_33
Veteran |
11-Jan-2008 08:47
|
||||
|
x 0
x 0 Alert Admin |
the party have started a while only....still have some length to go....it have not stike 12o'clock right? anyway thanks for your company.... nothing wrong to take your profit when objective is meet.... 
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Superdad
Member |
11-Jan-2008 08:36
|
||||
|
x 0
x 0 Alert Admin |
i am completely out at $1.00 best of luck to all those vested and hope it surges to its targeted price of 1.30 soon thank you Biosensor for your generous handout |
||||
| Useful To Me Not Useful To Me | |||||
|
allright
Senior |
11-Jan-2008 01:14
|
||||
|
x 0
x 0 Alert Admin |
Well lets hope latest end Jan 2008... | ||||
| Useful To Me Not Useful To Me | |||||
|
bengster68
Master |
11-Jan-2008 00:56
|
||||
|
x 0
x 0 Alert Admin |
|
||||
| Useful To Me Not Useful To Me | |||||
|
cwwan1
Member |
11-Jan-2008 00:21
|
||||
|
x 0
x 0 Alert Admin |
Ya, how come like that? But one thing i know is Biomatrix is 0% TLR. lets waits for the leader trial, i am sure biomatrix beat cypher flat. | ||||
| Useful To Me Not Useful To Me | |||||
|
bengster68
Master |
11-Jan-2008 00:09
|
||||
|
x 0
x 0 Alert Admin |
10 months, the cumulative MACE rate for the Genous group (GRS) was 4% versus 22% for the combined TAXUS and CYPHER group (DES). For the MACE components, the cumulative rate of target vessel revascularization (TVR) was 1% for GRS versus 11.8% for DES, the cumulative rate of myocardial infarction (MI) was 1% for GRS versus 7.8% for DES, and the cumulative mortality rate was 2% for GRS versus 7.8% for DES. In addition, the cumulative rate for stent thrombosis was 2% for GRS versus 5.8% for DES. How come the figures are so high for Cypher and Taxus? 22% MACE rate at 10 months for Cyhper and Taxus was never seen before in the history of 10 months clinical trial and is very jia lat... basically can ban those stents already. They are MACE , TVR, MI and mortality rates for Cypher and Taxus at other very large scale clinical trials yeilded much lower figures. I suspect it is a very small scale trial and if Genous had the "better condition" patients while the others are the "more serious case" patients, then the results will be very skewed. Previously, I posted a clinical trial of Genous on 17/11/2007 and here is the extract: "As for OrbusNeich's genous bio-engineered stent, they didn't seem to make an impact in the stent industry despite having their CE approved back in 2005. At 6 months results, Genous TLR is 5.3% VS Taxus' 4.3%. TVF for Genous is 8.4% VS 5.4%. Late-loss is 0.48mm which is BMS standard. There were also thrombosis cases for genous which OrbusNeich claim can be eliminated with their EPC coated stents." Walau 180 degree change in RCT performance. So weird. Something is not right. OrbusNeich kelong the clinical trial??? |
||||
| Useful To Me Not Useful To Me | |||||
|
cashiertan
Elite |
10-Jan-2008 23:45
|
||||
|
x 0
x 0 Alert Admin |
anyway tomolo trading just be prepared there may be gap covering. mentioned this becoz hope ppl dun get panic when the see the price drop tomolo. however do consider to sell if it break 95c tomolo. can always buy back later when price consolidate. Cheong AH! |
||||
| Useful To Me Not Useful To Me | |||||
|
cwwan1
Member |
10-Jan-2008 23:08
|
||||
|
x 0
x 0 Alert Admin |
Patients who received OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, had significantly fewer major cardiac adverse events (MACE) than patients who received Boston Scientific's TAXUS or Johnson & Johnson's CYPHER drug-eluting stents in a study conducted at Federico II University of Naples in Naples, Italy. The results of the study were presented recently at the XXVIII National Congress of the Italian Society of Invasive Cardiology by Federico Piscione, M.D., the study's principal investigator and a professor with the university's Division of Cardiology, Department of Clinical Medicine and Cardiovascular Sciences. At clinical follow-up of 10 months, the cumulative MACE rate for the Genous group (GRS) was 4% versus 22% for the combined TAXUS and CYPHER group (DES). For the MACE components, the cumulative rate of target vessel revascularization (TVR) was 1% for GRS versus 11.8% for DES, the cumulative rate of myocardial infarction (MI) was 1% for GRS versus 7.8% for DES, and the cumulative mortality rate was 2% for GRS versus 7.8% for DES. In addition, the cumulative rate for stent thrombosis was 2% for GRS versus 5.8% for DES. "Our findings suggest that the deployment of Genous stents in a consecutive series of high-risk patients is safe and effective, with a significantly lower in-hospital incidence of MACE and a better long-term clinical outcome when compared to drug-eluting stents," said Piscione. "Genous is a viable alternative to drug-eluting stents, which have raised many safety concerns among the interventional cardiology community. Unlike TAXUS and CYPHER that elute cytotoxic agents to inhibit neointimal proliferation, Genous attracts circulating endothelial progenitor cells to rapidly build a layer of healthy tissue and promote long-term natural healing." The study involved 195 consecutive high-risk patients who underwent percutaneous coronary intervention (PCI) with either GRS or DES implantation at the university's cath lab. After PCI, patients who received GRS were prescribed dual antiplatelet therapy for one month, and patients who received DES were prescribed the same therapy for nine months. Complete clinical follow-up was obtained for 100% of the patient population. High risk was defined as advanced age, high rate of conventional risk factors for CAD, multivessel disease, multivessel stenting, depressed left ventricular ejection fraction. Genous is coated with an antibody to capture a patient's endothelial progenitor cells, and, therefore, accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of the Genous stent, EPCs can form an endothelial layer over the stent to provide protection against thrombus and minimize restenosis. The stent was developed by OrbusNeich, a global medical device company. |
||||
| Useful To Me Not Useful To Me | |||||
|
huatah
Veteran |
10-Jan-2008 23:01
|
||||
|
x 0
x 0 Alert Admin |
oic.. sori.. i didn't know tat de previous postings did mentioned tat production, etc, etc.. had been laid.. guess i had overlooked.. me just got de confirmation today.. hence just indicate here to share.. | ||||
| Useful To Me Not Useful To Me | |||||
x 0 
x 0